Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity

Inclusion criteria

• Abdominal obesity: Waist circumference for men should be above 102 cm and for women above 88 cm.
• Caucasian (because of skin fluorescence and capillary microscopy measurements)
• Aged 18-75 years

Exclusion criteria

• Diabetes (i.e. using anti-diabetic medication, fasting glucose >7.0 mmol/L, HbA1c >6.5%).
• Active or history of cardiovascular disease (e.g. stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
• Hyperlipidemia (defined as serum total cholesterol > 8 mmol/L or TG > 4 mmol/L)
• Smoking (>10 cigarettes per day)
• High alcohol usage (>4 U/day) or drug abuse
• Use of medication known to influence glucose metabolism, vascular function (e.g. glucocorticosteroids, NSAID's)
• Higher grade hypertension (> 179 mmHg SBP and/or > 109 mmHg DBP) in order not to expose subjects to unnecessary risks)
• Known allergic reaction to ultrasound contrast-agent
• Pulmonary or inflammatory disease
• Kidney failure or electrolyte disorders
• Use of dietary supplements or an investigational product within the previous month
• Unstable body weight (no drastic changes in life style before or during the intervention are allowed, this means no weight gain or loss >3 kg in the last two months)
• Pregnancy or lactation
• No change in use of oral anticonceptiva or IUD (12 weeks prior of during the intervention)
• Unwillingness to give up being a blood donor (or having donated blood) from 8 weeks prior to the start of the study and during the study
• Insufficient knowledge of the Dutch language